Bruce Neal's Publications

Liu Y, Li N, Yan N et alii
Protocol for a randomized controlled trial to test the acceptability and adherence to 6-months of walnut supplementation in Chinese adults at high risk of cardiovascular disease

Journal articles
2021
Nutrition Journal
Feng KY, Gogate J, Damaraju CV et alii
Canagliflozin Reduces All-cause Hospitalization in Patients with Type 2 Diabetes Mellitus

Conference Papers
2021
in METABOLISM-CLINICAL AND EXPERIMENTAL
Sarraju A, Li JW, Cannon CP et alii
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial

Journal articles
2021
American Heart Journal
Jardine M, Zhou Z, Lambers Heerspink HJ et alii
Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria

Journal articles
2021
Clinical Journal of the American Society of Nephrology
Ye N, Jardine MJ, Oshima M et alii
Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights from the CREDENCE Trial.

Journal articles
2021
Circulation
Yu J, Zhou Z, Mahaffey KW et alii
An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials

Journal articles
2021
International Journal of Cardiology
Neuen BL, Arnott C, Perkovic V et alii
Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes

Journal articles
2021
Diabetes
Yin X, Tian M, Neal B
Sodium Reduction: How Big Might the Risks and Benefits Be?

Journal articles
2021
Heart Lung and Circulation
Januzzi JL, Butler J, Sattar N et alii
Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study

Journal articles
2021
Diabetes care
Neuen BL, Ohkuma T, Neal B et alii
Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program

Journal articles
2021
American Journal of Kidney Diseases
Chow CK, Atkins ER, Billot L et alii
Ultra-low-dose quadruple combination blood pressure–lowering therapy in patients with hypertension: The QUARTET randomized controlled trial protocol

Journal articles
2021
American Heart Journal
Li C, Zhou Z, Neuen BL et alii
Sodium-glucose co-transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis

Journal articles
2021
Diabetes
Coyle D, Shahid M, Dunford E et alii
Estimating the potential impact of Australia’s reformulation programme on households’ sodium purchases

Journal articles
2021
BMJ Nutrition
Roth GA, Mensah GA, Johnson CO et alii
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study

Journal articles
2020
Journal of the American College of Cardiology
Bakris G, Oshima M, Mahaffey KW et alii
Effects of canagliflozin in patients with baseline eGFR <30 ml/min per 1.73 m2: Subgroup analysis of the randomized CREDENCE trial

Journal articles
2020
Clinical Journal of the American Society of Nephrology
Coyle DH, Shahid M, Dunford EK et alii
Correction to: Contribution of major food companies and their products to household dietary sodium purchases in Australia (International Journal of Behavioral Nutrition and Physical Activity, (2020), 17, 1, (81), 10.1186/s12966-020-00982-z)

Journal articles
2020
International Journal of Behavioral Nutrition and Physical Activity
Bablani L, Mhurchu CN, Neal B et alii
The impact of voluntary front-of-pack nutrition labelling on packaged food reformulation: A difference-in-differences analysis of the Australasian Health Star Rating scheme

Journal articles
2020
PLoS Medicine
Januzzi JL, Xu J, Li JW et alii
Effects of Canagliflozin on Amino-Terminal Pro–B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction

Journal articles
2020
Journal of the American College of Cardiology
Mahaffey KW, Li J, Chang T et alii
Independent predictors of heart failure in patients with type 2 diabetes and chronic kidney disease: modeling from the CREDENCE trial

Conference Papers
2020
in EUROPEAN HEART JOURNAL
Pan XF, Magliano DJ, Zheng M et alii
Seventeen-year associations between diet quality defined by the health star rating and mortality in australians: The australian diabetes, obesity and lifestyle study (ausdiab)

Journal articles
2020
Current Developments in Nutrition
Oshima M, Neuen BL, Jardine MJ et alii
Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial

Journal articles
2020
The Lancet Diabetes and Endocrinology
Matthews DR, Wysham C, Davies M et alii
Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program

Journal articles
2020
Diabetes
Arnott C, Neuen BL, Heerspink HJL et alii
The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program

Journal articles
2020
International Journal of Cardiology
Oshima M, Neal B, Toyama T et alii
Different eGFR decline thresholds and renal effects of canagliflozin: Data from the CANVAS program

Journal articles
2020
Journal of the American Society of Nephrology
de Zeeuw D, Arnott C, Li J-W et alii
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: analysis of the CREDENCE trial

Conference Papers
2020
in DIABETOLOGIA
Heerspink HJL, Oshima M, Jardine MJ et alii
Acute declines in eGFR during treatment with canagliflozin and its implications for clinical practice: insights from CREDENCE

Conference Abstracts
2020
in DIABETOLOGIA

Bruce Neal's Publications

Protocol for a randomized controlled trial to test the acceptability and adherence to 6-months of walnut supplementation in Chinese adults at high risk of cardiovascular disease

Canagliflozin Reduces All-cause Hospitalization in Patients with Type 2 Diabetes Mellitus

Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial

Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria

Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights from the CREDENCE Trial.

An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials

Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes

Sodium Reduction: How Big Might the Risks and Benefits Be?

Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study

Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program

Ultra-low-dose quadruple combination blood pressure–lowering therapy in patients with hypertension: The QUARTET randomized controlled trial protocol

Sodium-glucose co-transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis

Estimating the potential impact of Australia’s reformulation programme on households’ sodium purchases

Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study

Effects of canagliflozin in patients with baseline eGFR <30 ml/min per 1.73 m2: Subgroup analysis of the randomized CREDENCE trial

Correction to: Contribution of major food companies and their products to household dietary sodium purchases in Australia (International Journal of Behavioral Nutrition and Physical Activity, (2020), 17, 1, (81), 10.1186/s12966-020-00982-z)

The impact of voluntary front-of-pack nutrition labelling on packaged food reformulation: A difference-in-differences analysis of the Australasian Health Star Rating scheme

Effects of Canagliflozin on Amino-Terminal Pro–B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction

Independent predictors of heart failure in patients with type 2 diabetes and chronic kidney disease: modeling from the CREDENCE trial

Seventeen-year associations between diet quality defined by the health star rating and mortality in australians: The australian diabetes, obesity and lifestyle study (ausdiab)

Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial

Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program

The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program

Different eGFR decline thresholds and renal effects of canagliflozin: Data from the CANVAS program

The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: analysis of the CREDENCE trial

Acute declines in eGFR during treatment with canagliflozin and its implications for clinical practice: insights from CREDENCE

The George Institute for Global Health

The George Institute country sites:

Acknowledgement of Country